Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Connection

Frank Scott to Inflammatory Bowel Diseases

This is a "connection" page, showing publications Frank Scott has written about Inflammatory Bowel Diseases.

 
Connection Strength
 
 
 
7.173
 
  1. Constant BD, Scott FI. The PA System: Is Prior Authorization for Dose Escalation of IBD Biologic Therapy a Tolerable Alternative or a Perpetual Annoyance? Dig Dis Sci. 2023 12; 68(12):4279-4281.
    View in: PubMed
    Score: 0.660
  2. Scott FI, Ehrlich O, Wood D, Viator C, Rains C, DiMartino L, McArdle J, Adams G, Barkoff L, Caudle J, Cheng J, Kinnucan J, Persley K, Sariego J, Shah S, Heller C, Rubin DT. Creation of an Inflammatory Bowel Disease Referral Pathway for Identifying Patients Who Would Benefit From Inflammatory Bowel Disease Specialist Consultation. Inflamm Bowel Dis. 2023 08 01; 29(8):1177-1190.
    View in: PubMed
    Score: 0.652
  3. Haydek JP, Scott FI. Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with IBD. Aliment Pharmacol Ther. 2022 09; 56(5):896-897.
    View in: PubMed
    Score: 0.612
  4. Constant BD, de Zoeten EF, Stahl MG, Vajravelu RK, Lewis JD, Fennimore B, Gerich ME, Scott FI. Delays Related to Prior Authorization in Inflammatory Bowel Disease. Pediatrics. 2022 03 01; 149(3).
    View in: PubMed
    Score: 0.591
  5. Ahmed W, Scott FI. Closing the Gap: the Real-World Risk of Serious Infections With Vedolizumab in Comparison With Anti-TNF Therapy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022 02; 20(2):e28-e30.
    View in: PubMed
    Score: 0.560
  6. Scott FI. Infliximab Versus Biosimilars for IBD: Is It Better to Fight Than Switch? Dig Dis Sci. 2020 08; 65(8):2158-2160.
    View in: PubMed
    Score: 0.530
  7. Vachon A, Scott FI. The treatment approach to inflammatory bowel disease in 2020. Curr Opin Gastroenterol. 2020 07; 36(4):247-256.
    View in: PubMed
    Score: 0.527
  8. Scott FI, Rubin DT, Kugathasan S, Bousvaros A, Elson CO, Newberry RD, Melmed GY, Pekow J, Fleshman JW, Boyle BM, Mahadevan U, Cannon LM, Long MD, Cross RK, Ha CY, Lasch KL, Robinson AM, Rafferty JF, Lee JJ, Dahl KDC, Weaver A, Shtraizent N, Honig G, Hurtado-Lorenzo A, Heller CA. Challenges in IBD Research: Pragmatic Clinical Research. Inflamm Bowel Dis. 2019 05 16; 25(Suppl 2):S40-S47.
    View in: PubMed
    Score: 0.487
  9. Scott FI, Singh S. Bridging Gaps in Evidence-based Clinical Practice in Inflammatory Bowel Diseases: Observational Comparative Effectiveness Research for the Win. Clin Gastroenterol Hepatol. 2019 08; 17(9):1726-1728.
    View in: PubMed
    Score: 0.475
  10. Hans AK, Scott FI. Editorial: which inflammatory bowel disease patients should be screened for Epstein-Barr virus infection? Aliment Pharmacol Ther. 2018 11; 48(10):1158-1159.
    View in: PubMed
    Score: 0.469
  11. Vajravelu RK, Osterman MT, Aberra FN, Roy JA, Lichtenstein GR, Mamtani R, Goldberg DS, Lewis JD, Scott FI. Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization. Inflamm Bowel Dis. 2017 12 19; 24(1):217-226.
    View in: PubMed
    Score: 0.442
  12. Constant BD, Albenberg L, Mitchel EB, De Zoeten EF, Clapp JT, Scott FI. Prior Authorizations Delay Therapy, Impact Decision-making, and Lead to Adverse Events in Inflammatory Bowel Disease: 2022 Provider Survey. Clin Gastroenterol Hepatol. 2024 02; 22(2):423-426.
    View in: PubMed
    Score: 0.162
  13. Holmer AK, Luo J, Russ KB, Park S, Yang JY, Ertem F, Dueker J, Nguyen V, Hong S, Zenger C, Axelrad JE, Sofia A, Petrov JC, Al-Bawardy B, Fudman DI, Llano E, Dailey J, Jangi S, Khakoo N, Damas OM, Barnes EL, Scott FI, Ungaro RC, Singh S. Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study. Clin Gastroenterol Hepatol. 2023 06; 21(6):1598-1606.e5.
    View in: PubMed
    Score: 0.157
  14. Kim HS, Hernaez R, Sansgiry S, Waljee AK, Scott FI, Lewis JD, El-Serag HB, Hou JK. Comparative Effectiveness of Surveillance Colonoscopy Intervals on Colorectal Cancer Outcomes in a National Cohort of Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022 12; 20(12):2848-2857.e2.
    View in: PubMed
    Score: 0.148
  15. Almario CV, Kogan L, van Deen WK, Scott FI, Singh S, Hou JK, Lum D, Aguilar H, Betteridge J, Flynn A, Gerich M, Kaufman L, Mattar MC, Mize C, Ostrov A, Shah SA, Younes Z, Weaver SA, Heller C, Siegel CA, Melmed GY. Health Economic Impact of a Multicenter Quality-of-Care Initiative for Reducing Unplanned Healthcare Utilization Among Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2021 12 01; 116(12):2459-2464.
    View in: PubMed
    Score: 0.145
  16. Vajravelu RK, Copelovitch L, Osterman MT, Scott FI, Mamtani R, Lewis JD, Denburg MR. Inflammatory Bowel Diseases Are Associated With an Increased Risk for Chronic Kidney Disease, Which Decreases With Age. Clin Gastroenterol Hepatol. 2020 09; 18(10):2262-2268.
    View in: PubMed
    Score: 0.126
  17. Kinnucan J, Binion D, Cross R, Evans E, Harlen K, Matarese L, Mullins A, O'Neal B, Reiss M, Scott FI, Weaver A, Rosenberg J. Inflammatory Bowel Disease Care Referral Pathway. Gastroenterology. 2019 07; 157(1):242-254.e6.
    View in: PubMed
    Score: 0.121
  18. Lewis JD, Scott FI, Brensinger CM, Roy JA, Osterman MT, Mamtani R, Bewtra M, Chen L, Yun H, Xie F, Curtis JR. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-a-Directed Therapy for Inflammatory Bowel Disease. Am J Gastroenterol. 2018 03; 113(3):405-417.
    View in: PubMed
    Score: 0.111
  19. Mamtani R, Clark AS, Scott FI, Brensinger CM, Boursi B, Chen L, Xie F, Yun H, Osterman MT, Curtis JR, Lewis JD. Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study. Arthritis Rheumatol. 2016 10; 68(10):2403-11.
    View in: PubMed
    Score: 0.102
  20. Scott FI, Mamtani R, Brensinger CM, Haynes K, Chiesa-Fuxench ZC, Zhang J, Chen L, Xie F, Yun H, Osterman MT, Beukelman T, Margolis DJ, Curtis JR, Lewis JD. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. JAMA Dermatol. 2016 Feb; 152(2):164-72.
    View in: PubMed
    Score: 0.097
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)